Suchergebnisse - "Brufsky, Adam"

PubPharm (533)

41

A unique view of SARS-CoV-2 through the lens of ORF8 protein

enthalten in: bioRxiv.org | 2022

von Hassan, S. | Ghosh, S. | Attrish, D. | +18

42

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer

enthalten in: NPJ breast cancer | 2022

von Rugo, H. | Brufsky, A. | Liu, X. | +9

43

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: Breast cancer research and treatment | 2022

von O'Shaughnessy, J. | Brufsky, A. | Rugo, H. | +15

44

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer : Flatiron Database Analysis

enthalten in: Clinical breast cancer | 2022

von Patt, D. | Liu, X. | Li, B. | +3

45

Correction to : Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

ErratumFor: Breast Cancer Res Treat. 2022 Jun;193(3):555-564. - PMID 35230585

46

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer : the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

ErratumIn: Breast Cancer Res Treat. 2022 May 4;:. - PMID 35507135

47

An Issue of Concern: Unique Truncated ORF8 Protein Variants of SARS-CoV-2

enthalten in: bioRxiv.org | 2022

von Hassan, S. | Kodakandla, V. | Redwan, E. | +18

48

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: Breast cancer research and treatment | 2022

von O’Shaughnessy, J. | Brufsky, A. | Rugo, H. | +15

49

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: Breast cancer research and treatment | 2022

von O’Shaughnessy, J. | Brufsky, A. | Rugo, H. | +15

50

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: Breast cancer research and treatment | 2022

von O’Shaughnessy, J. | Brufsky, A. | Rugo, H. | +15